Drug firm Glenmark Pharmaceuticals today said it is initiating investigational new drug-enabling studies for a novel antibody which has potential to kill cancer cells. The discovery and initiation of studies for the antibody, GBR 1372, is being done by the company’s wholly-owned subsidiary Glenmark
8.26 PM Sep 6th
Source:India Infoline - Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 830, an anti-OX40 monoclonal antibody. GBR 830 has
3.26 PM Feb 5th 2013
Source:The Hindu BusinessLine - New Delhi, Feb 4: Glenmark Pharmaceuticals today said it has initiated studies for the development of a new molecule ‘GBR 830’, which could possibly be used to treat diseases like Arthritis (RA) and bowel disease. In a statement, the Mumbai-headquartered firm said
3.09 PM Feb 5th 2013
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.